Patent ID: 9487582
Filing Date: 2016-11-08
CPC Classification: A61K,A61P,C07K,G01N

Claim Text:
1. A method for treating pancreatic cancer in a subject, comprising administering to a human subject diagnosed with pancreatic cancer an amount of an anti-human progastrin (anti-hPG) antibody sufficient to provide therapeutic benefit, wherein said anti-hPG antibody is a C-terminal monoclonal antibody that binds to a C-terminal region of human progastrin polypeptide (hPG) wherein the anti-hPG antibody comprises: (i) a heavy chain variable region in which CDR1 comprises the amino acid sequence of VH CDR 1.8 (SEQ ID NO:37), CDR2 comprises the amino acid sequence of VH CDR 2.8 (SEQ ID NO:41), and CDR3 comprises the amino acid sequence of VH CDR 3.8 MO ID NO:45), and a light chain variable region in which CDR1 comprises the amino acid sequence of VL CDR 1.8 (SEQ ID NO:49), CDR2 comprises the amino acid sequence of VL CDR 2.8 (SEQ ID NO:52), and CDR3 comprises the amino acid sequence of VL CDR 3.8 (SEQ ID NO:55); or (ii) a heavy chain variable region in which CDR1 comprises the amino acid sequence of VH CDR 1.13 (SEQ ID NO:38), CDR2 comprises the amino acid sequence of VH CDR 2.13 (SEQ ID NO:42), and CDR3 comprises the amino acid sequence of VH CDR 3.13 (SEQ ID NO:46), and a light chain variable region in which CDR1 comprises the amino acid sequence of VL CDR 1.13 (SEQ ID NO:50), CDR2 comprises the amino acid sequence of VL CDR 2.13 (SEQ ID NO:53), and CDR3 comprises the amino acid sequence of VL CDR 3.13 (SEQ ID NO:56).